A novel JEV vaccine with a favorable safety profile and global distribution strategy

In Partnering and Corporate strategy, R&D by Maria RelakiLeave a Comment

Jeffrey Hackman - IntercellJeff Hackman is the Sr. Vice President, Commercial Operations for Intercell AG and President and CEO of Intercell USA. In this role, he supervises the global marketing and sales efforts, and commercial partnerships for the company focusing on the successful global launch of Intercell's first licensed product, IXIARO/JESPECT®(Japanese Encephalitis vaccine).

And this is exactly what he talked to us about at the World Vaccine Congress in Washington DC in April 2012.

We had the pleasure to find out more about the preclinical and clinical features of the novel high quality JEV vaccine Intercell is currently working on.

Jeff also went into detail of Intercell's biotech strategy to market the vaccine for travellers and armed forces.

A key take-away point is that partnerships are key to move projects like these forward and Intercell is no exception. Through a partnership concept Jeff Hackman is leading these efforts to move the vaccine into the pediatric arena of endemic countries.

To find out more about the concept and the launch of Intercell's JEV vaccine, download the full presentation here.

Mr Hackman joined Intercell in March 2009, with global commercial product marketing and sales experience in US, Europe, and Asia. Mr. Hackman's experience spans over a 24 year pharma/biotech career involving several product launches in vaccines, Mabs, and antibiotics,. His responsibilities have focused on marketing, sales, strategic product development, government sales and contracting, business development, partnership management, biodefense markets, and product lifecycle management.

Leave a Comment

Current ye@r *